![]() | ![]() |
Formats:
|
||||||||||||||||||||||||||||||||||||
Copyright © 2008 Hoffman et al; licensee BioMed Central Ltd. Expression of Groucho/TLE proteins during pancreas development 1Department of Cancer Endocrinology, BC Cancer Research Center, 675 West 10th Avenue, Vancouver, B.C., V5Z 1L3, Canada 2Department of Surgery, Faculty of Medicine, University of British Columbia, 910 West 10th Avenue, Vancouver, B.C., V5Z 4E3, Canada Corresponding author.Brad G Hoffman: bhoffman/at/bccrc.ca; Bogard Zavaglia: bzavagli/at/bccrc.ca; Mike Beach: mbeach/at/bccrc.ca; Cheryl D Helgason: chelgaso/at/bccrc.ca Received April 28, 2008; Accepted September 8, 2008. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background The full-length mammalian homologs of groucho, Tle1, 2, 3, and 4, act as transcriptional corepressors and are recruited by transcription factors containing an eh1 or WRPW/Y domain. Many transcription factors critical to pancreas development contain a Gro/TLE interaction domain and several have been shown to require Gro/TLE interactions for proper function during neuronal development. However, a detailed analysis of the expression patterns of the Gro/TLE proteins in pancreas development has not been performed. Moreover, little is known about the ability of Gro/TLE proteins to interact with transcription factors in the pancreas. Results We describe the expression of Gro/TLE family members, and of 34 different transcription factors that contain a Gro/TLE interaction motif, in the pancreas utilizing nine SAGE libraries created from the developing and adult pancreas, as well as the GenePaint database. Next, we show the dynamic expression of Tle1, 2, 3, 4, 5 and 6 during pancreas development by qRT-PCR. To further define the cell-type specificity of the expression of these proteins we use immunofluorescence to co-localize them with Pdx1 at embryonic day 12.5 (E12.5), Ngn3 at E14.5, Pdx1, Nkx2-2, Insulin, Glucagon, Pancreatic polypeptide and Somatostatin at E18.5, as well as Insulin and Glucagon in the adult. We then show that Tle2 can interact with Nkx2-2, Hes1, Arx, and Nkx6-1 which are all critical factors in pancreas development. Finally, we demonstrate that Tle2 modulates the repressive abilities of Arx in a β-cell line. Conclusion Although Tle1, 2, 3, and 4 show overlapping expression in pancreatic progenitors and in the adult islet, the expression of these factors is restricted to different cell types during endocrine cell maturation. Of note, Tle2 and Tle3 are co-expressed with Gro/TLE interaction domain containing transcription factors that are essential for endocrine pancreas development. We further demonstrate that Tle2 can interact with several of these factors and that Tle2 modulate Arx's repressive activity. Taken together our studies suggest that Gro/TLE proteins play a role in the repression of target genes during endocrine cell specification. Background Many of the transcription factors important in pancreas development are, or are thought to act as, repressors of target genes. For example, Nkx2-2 acts as a transcriptional repressor in the developing neural tube [1,2] and represses ghrelin cell specification during pancreas development [3]. Pax4 represses the α-cell transcription factor Arx, which in turn represses Pax4 expression [4]. During pancreas development Nkx6-1 acts as a context dependent transcriptional activator or repressor, activating its own transcription while more broadly repressing gene expression [5,6]. Nkx6-2 is a repressor of Dbx1 in neuronal development [7]. In each of these cases, both in the pancreas and in neuronal development, transcription factor mediated repression of target genes requires the recruitment of cofactors. For many of these transcription factors homologs of Groucho, called the Groucho/Transducin-like enhancer of split (Gro/TLE) family, fulfill this role [7,8]. In Drosophila groucho (Gro) acts as a master repressor [9] and regulates transcriptional repression through interactions with Hairy, Hairy related, and Runt family proteins via a WRPW/Y motif, as well as with Dorsal, Engrailed, and Tcf family proteins via an unrelated eh1 (FxIxxIL) motif [10]. Evidence suggests that Gro recruits histone deacetylases (HDACs) that modify the local chromosomal state, silencing gene transcription. There are at least six mouse homologs of Gro (Tle1-6), which all have direct human orthologs. Tle1, 2, 3, 4, and 6 are full-length GRO subfamily members containing a highly conserved WD-repeat domain at their carboxy termini and a glutamine rich (Q) domain at their amino terminal end. Linking these domains is a weakly conserved central region. Tle5 (AES), that lacks much of the central region and the WD-repeat domain, acts as a dominant negative repressor of GRO subfamily members [9-12]. It has been reported that Tle1 and Tle3 have non-overlapping expression patterns in the brain and spinal cord, while Tle1, 2, and 4 were shown to be differentially expressed in in vitro models of neural and chondrocytic determination [13,14]. Later studies showed that Tle1-4 have unique but overlapping expression patterns, with the overlaps occurring in putative precursor populations [15]. These results imply that each member of the Gro/TLE family has unique functions in specific cell types, despite the fact they may have similar promiscuous binding affinities for numerous WRPW/Y and eh1 motif containing proteins, and possibly redundant functions in progenitor cell types. Numerous studies have begun to dissect the roles of the Gro/TLE family members in various developmental systems. To date, Gro/TLE mediated repression has been implicated in pituitary and kidney organogenesis, hematopoiesis, and development of both bone and the eye [16-22]. These studies have revealed a number of pathways and transcriptional repressors utilizing Gro/TLE proteins. For example, all Tcf HMG box transcription factors interact with Tle1, 2, 3, and 4 and repress transactivation in a β-catenin -Tcf reporter gene assay, suggesting a role for the Gro/TLE proteins in Wnt signaling [23]. In addition, Foxa2 (HNF3β) has been shown to interact with Tle1 in Hela and HepG2 cells [24]. The majority of work, however, has focused on understanding the function of the mammalian Gro/TLE proteins in neuronal development. Notch signaling acts to restrict the neural potential of progenitors by antagonizing expression of pro-neural genes. Both Tle1 and Tle2 interact directly with Hes1 and are vital to it's repressive abilities [25-27]. Tle1 also interacts with BF-1 (Foxg1), a regulator of neuronal differentiation [28], mediating the interaction between BF-1 and Hes1 [28]. Several homeodomain transcription factors (i.e. Nkx6-1, Nkx6-2, and Nkx2-2) important in pancreas development are also essential to patterning neuronal specification in the ventral neural tube and interact with Gro/TLE proteins [8,29,30]. A cross-repressive model whereby these transcription factors repress genes involved in the specification of opposing cell types has been proposed [7]. The Gro/TLE family members are a vital component of this model and ectopic expression of Tle5, a dominant negative inhibitor of Gro/TLE mediated repression, perturbs neural tube patterning by extending the expression domains of both Nkx2-2 and Nkx6-1 [8]. In this work we describe the expression of Gro/TLE family members utilizing nine SAGE libraries created from the developing and adult pancreas. Additionally we identify, and assess the expression of, 34 different transcription factors that contain a Gro/TLE interaction motif in these libraries, and further demonstrate that at least 13 of these are expressed in the endocrine lineage. We then show the dynamic expression of Tle1 through 6 during pancreas development by qRT-PCR. The cell-type specificity of Tle1, 2, 3, and 4 expression was assessed using IHC to co-localize each with Pdx1 at E12.5, Ngn3 at E14.5, Pdx1, Nkx2-2, Insulin, Glucagon, Pancreatic polypeptide and Somatostatin at E18.5, and Insulin and Glucagon in the adult. We then focus on Tle2, as it was expressed widely in endocrine pancreas development, and show that it can interact with Nkx2-2, Nkx6-1, Hes1 and Arx which are all essential in proper endocrine pancreas development. Finally, we demonstrate that Tle2 can modulate the repressive abilities of Arx and that this modulation is dependent upon Arx's Gro/TLE interaction domain. Results Identification of Gro/TLE proteins and putative Gro/TLE interacting proteins in the developing pancreas We first assessed the expression of the Gro/TLE family members in nine Serial Analysis of Gene Expression (SAGE) libraries generated from the developing and adult pancreas [31,32]. This data revealed the differential expression of Tle1 through Tle6, with high levels of both Tle5 and Tle6, at various stages of pancreas development (Table 1). No tags unambiguously map to Tle4 so it could not be assessed. Since the Gro/TLE proteins interact with transcription factors containing an eh1 or WRPW/Y domain we assessed the expression of the 34 factors present in our pancreas SAGE libraries. Included in this group are several factors essential for proper endocrine cell specification and maturation such as Hes1, Foxa2, Nkx2-2, and Pou3f4 (Brn4) (Table 1). Arx and Nkx6-1, which are essential to proper α- and β-cell development respectively, and contain an eh1 domain, could not be detected as Arx does not produce an unambiguous tag while Nkx6-1 does not contain a NlaIII site and thus does not produce a SAGE tag.
We then used the GenePaint http://www.genepaint.org database to assess the staining patterns of these genes in the E14.5 pancreas. Tle 2 and 3 both showed modest staining throughout the epithelium and mesenchyme, while Tle1 staining was found predominantly in the mesenchyme (Figure (Figure1A1A
qRT-PCR analysis of Gro/TLE genes in pancreas development To determine the overall expression profiles of these genes in pancreas development we assessed their expression by qRT-PCR from E11.5 through to adult islets (Figure (Figure2).2
Expression of Gro/TLE proteins at the start of the secondary transition To determine the cell type specificities of Tle1-4 we first analyzed their co-expression with Pdx1, whose expression marks the first appearance of cells capable of giving rise to the endocrine and exocrine pancreas as well as the duodenum [37,38] (Figure (Figure33
Expression of Gro/TLE proteins at the end of the secondary transition During the secondary transition endocrine progenitors lose expression of Notch signaling components, such as Hes1, and begin to express the bHLH factor Ngn3. In neuronal development Tle1 expression is likewise lost during neural specification of progenitors. To see if a similar process occurs in the pancreas we co-localized Tle1-4 with Ngn3 in the E14.5 developing pancreas. Unlike at E12.5 where Tle1-3 were expressed throughout the pancreatic epithelium these factors clearly showed more restricted expression at E14.5 (Figure (Figure44
Expression of Gro/TLE proteins at E18.5, after the secondary transition Beyond being implicated in controlling progenitor cell maintenance, Gro/TLE proteins also play a role in the maturation of a wide variety of specialized cell types. As previously mentioned many of the transcription factors that play significant roles in proper endocrine cell specification and maturation contain a Gro/TLE interaction domain. To determine which Gro/TLE family members are co-expressed with, and thus might interact with, these factors we co-localized the expression of Tle1 through 4 with Pdx1, Nkx2-2, Insulin, Glucagon, Pancreatic polypeptide, and Somatostatin, which between them mark the four predominant endocrine cell types in the pancreas, at E18.5. Tle1 was found only in a few endocrine cells and its expression partially over-lapped only with Pdx1, which at this time point is restricted to β and δ cells. Tle1 expression was not seen in either Insulin or Glucagon positive cells. However it was found in cells that stained for the δ cell marker Somatostatin as well as in cells that stained for Pancreatic polypeptide (PP) (Figure (Figure6).6
Expression of Gro/TLE proteins in the adult Our qRT-PCR data suggests that the expression of Tle1, 2, and 3 peaks in the adult islets, while expression of Tle4 is almost as high as seen at E11.5. To determine if these genes show cell type specificity of expression within adult islets we next co-localized them with Insulin and Glucagon. Tle1, 2, 3 and 4 expression was quite broad within islets cell types, although Tle4 staining was noticeably weaker. Each of these proteins co-localized with Insulin in the majority of Insulin positive cells. However, in each case a number of cells positive only for Insulin were identified (Figure (Figure7).7
Interactions between Tle2 and transcription factors essential to proper pancreas development Based on our expression profiling results Tle2 and Tle3 are the most likely candidates to be functional co-repressors for critical endocrine cell transcriptional repressors such as Nkx2-2, Nkx6-1, and others. In support of this, Tle3 interacts with Nkx2-2 in the pancreas [3] and knocking in a mutant Nkx2-2 containing the activation domain but not the Gro/TLE interaction domain produces a phenotype similar to the Nkx2-2 knock out [3] demonstrating that this domain is critical to proper Nkx2-2 function. However, the transcription factors that Tle2 interacts with in the developing pancreas are not known. Thus to determine if Tle2 interacts with transcription factors critical to key stages in pancreas development we used co-immunoprecipitation in the Min6 β-cell line. We first attempted to determine if Tle2, like Tle3, can interact with Nkx2-2 that is essential for the proper specification and maturation of α, β, and PP cells. Anti-Nkx2-2 blots of material immunoprecipitated using an anti-Tle2 antibody produced an ~30 kDa band that was not seen in controls (rabbit IgG used in immunoprecipitation) but was found in western blots of whole cell lysate (Figure (Figure8A).8A
Since Arx is able to convert mature β-cells into cells with an α-cell phenotype, we hypothesized that Gro/TLE-Arx interactions might be important to this ability. To assess this possibility we used a rat insulin promoter (RIP) reporter driving the expression of Enhanced Green Fluorescent Protein (EGFP). Transfection of the RIP-EGFP reporter with a Tle2 expression vector modestly reduced the green fluorescence intensity (Figure (Figure9).9
Discussion Our qRT-PCR and IHC data indicate that the Gro/TLE proteins are expressed throughout pancreas development and suggest that they may act at multiple stages of pancreas development. Interestingly, we see the expression of all four Gro/TLE factors in the pancreatic mesenchyme. In our GenePaint analysis we identified two transcription factors with a Gro/TLE interaction domain expressed in the mesenchyme, Nkx2-3 and Tcf4. Tcf4 can interact with Gro/TLE proteins [23] although the significance of these, and any interactions between Nkx2-3 and Gro/TLE proteins, in the pancreatic mesenchyme remains to be elucidated. Tle1, 2, and 3 were expressed throughout the epithelium in the pancreas prior to the secondary transition, while at E18.5 only Tle2 and Tle3 were broadly expressed in the various developing endocrine cell types. We identified 13 different transcription factors also expressed in the endocrine lineage that contain Gro/TLE interaction domains. Many of these factors have known roles in pancreas development including Hes1 that is essential for proper endocrine specification, as well as Foxa2, Nkx2-2, Nkx6-1, and Pou3f4 (Arx) that are essential for proper endocrine cell maturation. The presence of these putative interacting transcription factors that are essential to various steps of pancreas development in our SAGE libraries further supports our hypothesis that the Gro/TLE proteins play a role during multiple phases of pancreas development. At the initiation of pancreas development (~E8.5) pancreatic epithelial precursor cells express Pdx1, although scattered Pdx1 negative Glucagon positive cells can be found. The co-expression of Tle1, 2 and 3 at E12.5 agrees with previous studies indicating that Gro/TLE expression overlaps in progenitor cell populations in other tissues. During neuronal development it has been suggested the primary role of the Gro/TLE factors is to maintain cells in the progenitor state through interactions with Hes1 [46], and they likely play this same role in the pancreas at this time. The differentiation of pancreatic progenitors into the various endocrine precursor cell types is under the control of Notch signaling, via lateral inhibition [47]. During this phase of pancreas development (E12.5–E14.5), called the secondary transition, committed endocrine progenitor cells are defined by their expression of Neurogenin 3 (Ngn3) [38] whose expression is otherwise repressed by Hes1 [47]. At this time point we identified Ngn3 negative Tle2/3 positive cells that likely represent duct cell precursors generated from pancreatic progenitors in which active Notch signaling has repressed Ngn3 activation. In addition, we find Ngn3 Tle2/3 double positive cells that showed generally dim Ngn3 staining, suggestive of precursors in which an endocrine fate has yet to be fully established. Last we find Ngn3 bright cells that are Tle2/3 negative and likely represent committed endocrine precursors. As Tle1 and Tle4 are not expressed in the epithelium at this time, these cells represent cells in which none of the traditional Gro/TLE co-repressor factors are present, indicating that the belief that these factors are ubiquitous throughout pancreas development is incorrect. Regardless, the wide expression of Tle1, 2, and 3 prior to the secondary transition, and the obvious disappearance of Tle2 and Tle3 with concomitant appearance of Ngn3, suggests that these factors play a role in Notch mediated lateral inhibition. Our demonstration that Tle2 can interact with Hes1 in pancreas cells, as it does in neural development [27], provides additional support for this hypothesis. By E18.5 Tle2 and Tle3 expression are clearly reactivated and both were expressed broadly in endocrine cell types, in agreement with our qRT-PCR data. Our E18.5 co-localization data showed that Tle1 is expressed in Pdx1 (that marks β and δ cells), Nkx2-2 (that marks α, β, and PP cells), PP, and Somatostatin positive cells, but not in Insulin or Glucagon positive cells suggesting that it is expressed in δ and PP cell types, but not in α or β cells. Tle2 co-localized with all the markers tested, indicating that is expressed in α, β, δ and PP cell types. Tle3 co-localized with all of the markers tested with the exception of PP, and in agreement with this, Nkx2-2 positive Tle3 negative cells were found, indicating that Tle3 is expressed in α, β, and δ cell types but not in PP cells. Tle4 was the least abundant of the four Gro/TLE family members assessed and co-localized with none of the markers tested suggesting Tle4 may be expressed specifically in ghrelin producing ε cells, although this remains to be confirmed. The obvious co-expression of the Gro/TLE proteins in islet cells, as was found in pancreatic progenitors at E12.5, is intriguing. Also of interest is the presence of rare Gro/TLE negative, Insulin positive cells. Gro/TLE proteins have been implicated in controlling the cell cycle [48] and we show that some of these Gro/TLE negative cells represent replicating β-cells. The expression and roles of these factors in ductal and acinar cells is also of interest. It is clear that more work needs to be done to further assess the roles of these factors in these cell types. In general our IHC data agree with the relative expression levels identified by qRT-PCR. In the qRT-PCR data, expression of Tle1 and 2 increased with development. At first glance this may seem in disagreement with the IHC data that indicates these factors decrease in expression in the epithelium. However, it is worth noting that they are still widely expressed in the surrounding mesenchyme. Tle3, on the other hand, was not expressed widely in the mesenchyme and its expression clearly does drop at E13.5 to E15.5 and is then reactivated at E18.5, as was found in the IHC data. Expression of all four of the Gro/TLE family members analyzed here was relatively high in the adult islets, again in agreement with the IHC data. Interestingly, the qRT-PCR expression profiles of Tle1-Tle4 are quite different from that of Tle5 and 6. Additionally from our GenePaint analysis Tle5 and Tle6 are both abundantly expressed throughout the pancreatic epithelium at E14.5. It is striking to note that these data suggest that Tle1, 2, and 3 are being shut off in Ngn3 positive endocrine precursors at roughly this time point. Tle5 is a dominant negative repressor of Tle1-Tle4 [9-12]. Likewise in neuronal development Tle6 (Grg6) antagonizes Tle1 interactions with BF-1 inhibiting BF-1 target gene repression and inducing neural progenitors to differentiate [49]. It is therefore likely these factors are acting to limit or prevent Gro/TLE mediated target repression during pancreas development and our expression data suggests this may play an important role during the secondary transition. Arx can repress Pax4 [4,50] and likely other β-cell specification genes and convert β-cells and β-cell progenitors into cells with an α-cell phenotype [44]. As this effect includes the loss of insulin expression we used a rat promoter insulin reporter construct to determine if Arx mediated repression of β-cell transcripts is Gro/TLE dependent. We found that co-expression of Arx and Tle2 enhanced repression of the insulin reporter as compared to Arx alone. However, this repression was not seen using an Arx construct lacking the eh1 domain. These data suggest that the repression of β-cell transcripts by Arx, which in turn leads to the repression of insulin and other genes characteristic of β-cells, is at least in part Gro/TLE dependent. Our results agree with studies on neuronal development that have defined a dual role for Gro/TLE factors in first controlling the differentiation of progenitor cell types and then later in the specification and maturation of specific cell types [46]. Our co-immunoprecipitation data demonstrates that Tle2 is able to interact with Nkx2-2, Nkx6-1, Hes1 and Arx, which are key controllers of endocrine cell specification and maturation. Further our IHC data indicates that Tle2 and Tle3, in particular, co-localize with these factors in pancreas development suggesting these interactions occur in vivo. Based on our results we propose a model for Gro/TLE action in the developing pancreas (Figure (Figure10).10
This model is, in part, based on the action of many of these same pancreas-essential transcription factors in neuronal development in which the interactions of cross repressive transcription factors and Gro/TLE proteins are critical for the proper inhibition of opposing factors [7,8]. Evidence suggesting that this model applies to pancreas development is beginning to emerge. For example, Nkx2-2 knock-out mice develop normal numbers of endocrine precursors which differentiate almost exclusively into ghrelin cells. Knock-in of a mutant Nkx2-2 composed of a DNA binding domain and a Gro/TLE interaction domain, but lacking an activation domain results in the development of primarily α-cells [3]. In contrast knocking in a mutant Nkx2-2 containing the activation domain but not the Gro/TLE interaction domain produces a phenotype similar to the Nkx2-2 knock out. These data suggest that repression of pro-ghrelin cell factors via Gro/TLE proteins is essential for the appropriate differentiation of a hypothetical tripotent (α, β, and ghrelin cell) precursor into a bipotent α/β cell precursor; whereas activation of target genes by Nkx2-2 is required for the proper differentiation of α/β progenitors into β-cells. In addition, Nkx6-1 and Nkx6-2 act in a cross repressive fashion during motor neuron development [7,30,51] and at least in the case of Nkx6-1 this repression is Gro/TLE dependent [8]. The expression of Nkx6-2 in the pancreas can be seen from E8.5 to E10.5 whereas Nkx6-1 becomes predominantly expressed starting at E11.5 [36] and Nkx6-1 knock-out mice have elevated levels of Nkx6-2 [52]. These data suggest that Nkx6-1 represses Nkx6-2 in a Gro/TLE dependent manner as occurs in motor neuron development [30]. Recent evidence indicates Nkx6-1 does not act to repress alternative cell fates directly [36] and instead acts to "prime" progenitor cells to be able to become β-cells. How the repressive versus activational activities of Nkx6-1 factor into this remains to be elucidated, although it seems likely that Nkx6-1 inhibits the expression of factors that repress pro-β cell factors such as Myt1, whose expression is reduced in Nkx6-1-/- mice [52]. On the other hand, Arx misexpression throughout the developing pancreas induces a clear loss of β and δ cells [44]. In fact, Arx is directly cross-repressive with Pax4 during pancreas development [4], further indicating that this factor represses genes essential to alternative cell fates and here we show that Arx interacts with Tle2 and that Tle2 modulates it's repressive effects. Conclusion At least 13 Gro/TLE interaction domain containing transcription factors are expressed in the endocrine pancreas lineage. These factors are known to control multiple critical steps in pancreatic development including progenitor cell specification as well as endocrine cell type specification and maturation. Tle1, 2, 3, and 4 are expressed dynamically during pancreas development. Tle1, 2, and 3 overlap in expression in the pancreatic epithelium at E12.5 suggesting they have redundant roles at this time. During the secondary transition their expression alters dramatically with Tle1 being lost from the epithelium and Tle2 and Tle3 expressed in only a subset of Ngn3 positive cells. This indicates that as Ngn3 expressing cells mature they lose Tle2 and Tle3 expression. However, by E18.5 these factors are re-activated and co-expressed in α, β, and δ cells, although only Tle2 was found in PP cells. Tle1 expressing cells were less abundant and we show Tle1 is expressed in δ and PP cells but not in α or β cells. Tle4 was only found in a rare subset of endocrine cells that did not express any of the markers tested. We also show that Tle2 can interact with factors involved in progenitor cell maintenance (Hes1), and endocrine cell maturation and specification (Nkx2-2, Nkx6-1, and Arx). Moreover, we provide evidence that Tle2 modulates the ability of Arx to repress the β-cell phenotype using a rat insulin reporter in a Gro/TLE interaction domain dependent fashion. In sum these data suggest that Tle1 – 4 are involved in a wide range of processes and are recruited by numerous transcription factors essential to proper pancreas development and function. Methods Mouse maintenance and islet isolation All mice were bred and maintained at the British Columbia Cancer Research Centre animal facility according to the guidelines of the Canadian Council on Animal Care. All protocols were approved by the University of British Columbia Animal Care Committee. Mice were housed in microisolator units, provided with Purina mouse food and autoclaved water ad libidum, and were maintained at 20°C ± 2°C under a light/dark cycle (light: 05:00–19:00 and dark: 19:00–05:00). Males were mated overnight with up to three females and females were checked for plugs before 9:30 the following morning. Plugged mice were considered to be 0.5 days post coitum (dpc). Islets were purified from 8–10 week old ICR males by collagenase digestion and gradient centrifugation as previously described [53]. SAGE data analysis SAGE data was analyzed using DiscoverySpace4 [54]. All SAGE libraries were generated and sequenced as part of the Mouse Atlas of Gene Expression [31] and Mammalian Organogenesis (MORGEN) projects. The data was filtered for sequence quality so that each tag had a 95% or greater probability of being correct, using the PHRED score quality assessment software [55]. Tag to gene mapping was performed using the mouse Refseq, MGC, and Ensembl databases using the DiscoverySpace program. Tags were considered sense position matches if they mapped in the sense orientation to the gene and antisense matches if they mapped in the opposite orientation. A tag was considered unambiguous if it matched a single sense position gene in all of the databases, and ambiguous if it mapped to multiple genes in a sense position regardless of the mapping position. The specificity of tags was determined by first obtaining the counts for the tags in 205 different Mouse Atlas Libraries. From this the mean of the tag counts in all the libraries (Ma) was determined and compared to tag count in the library of interest (Ci) to obtain the mean ratio (Mr). The total number of libraries the tag was found in, or library count, was next determined (La) as was the total counts of the tag in the library under analysis (Ci). The specificity (S) was then calculated as: S = Mr log1.3(Ci)/La. Thus tags with a high mean ratio that appear in relatively few libraries and are expressed more abundantly will have the highest specificities. Quantitative real-time PCR Probes for Tle1, 2, 3, and 4 as well as GAPDH were purchased from Applied Biosystems, Foster City, CA. An ABI 7500 real-time PCR system (Applied Biosystems) and Universal PCR Master Mix (Applied Biosystems) was used for all reactions. Six replicate cDNAs were obtained by reverse transcription (RT) of 1 μg of total RNA from newly isolated embryonic pancreas tissue or from Min6 cells for each RT. 10 ng of generated cDNA was used in each reaction with all reactions done in duplicate. Samples were normalized to Gapdh, and the fold increase compared to E11.5 pancreas or untreated Min6 cells (as appropriate) was calculated using 2-ΔΔCt [56]. GenePaint Analyses Images of in situ hybridization staining patterns for whole embryo sagittal sections were obtained from the GenePaint website (Visel et al., http://www.GenePaint.org). Higher magnification images of the area of the embryo containing the pancreas were obtained and the pancreas outlined. The brightness and contrast of some of the images was altered using Photoshop to better assess the staining pattern. Genes were then classified as showing trunk, tip, epithelial, mesenchymal or vasculature staining [57]. Immunohistochemistry Immunohistochemistry was performed on E12.5, E14.5, E18.5 embryonic, or adult, pancreas cryo-sections sections using the following antibodies: 1/100 dilution of guinea pig anti-Insulin (Stem Cell Technologies Inc.); 1/500 dilution of guinea pig anti-Glucagon (Linco); 1/100 dilution of guinea pig anti-PP (Millipore); 1/1000 dilution of mouse anti-Somatostatin (Santa Cruz); 1/100 dilution of mouse anti-Nkx2-2 (Developmental Studies Hybridoma Bank); 1/100 dilution of mouse anti-Ngn3 (Developmental Studies Hybridoma Bank); 1/10,000 dilution of guinea pig anti-Pdx1 (kindly provided by Christopher Wright); 1/1000 dilution of rabbit anti-Tle1 (kindly provided by Stefano Stifani); 1/1000 dilution of rabbit anti-Tle2 (Santa Cruz); 1/1000 dilution of rabbit anti-Tle3 (Santa Cruz); 1/1000 dilution of rabbit anti-Tle4 (kindly provided by Stefano Stifani); 1/100 dilution of rabbit anti-pan TLE (Santa Cruz); 1/100 dilution of mouse anti-PCNA. Primary antibodies were detected using a 1/2000 dilution of Alexa 488 or Alexa 546 conjugated anti-rabbit, anti-mouse, anti-goat or anti-guinea pig (Invitrogen) antibodies as appropriate. Cell Culture and Co-Immunoprecipitation Min6 cells were maintained in high glucose (4,500 mg/l) Dulbecco's Modified Eagle's Medium (DMEM; StemCell Technologies Inc.) supplemented with 10% fetal calf serum and 5 mM L-glutamine. Immunoprecipitations were performed on 3 × 106 Min6 cells or Min6 cells transfected with pCMS-6xHis-Arx and pCMS-Flag-Tle2, as appropriate. Cells were lysed and pre-cleared with 20 uL ProteinA-Sepharose (Rockland) to reduce background. Supernatants were incubated with 10 ug Rabbit Anti-Tle2 at 4° for 2 hours, and then with 20 uL of a 50% ProteinA-Sepharose slurry for 1 hour. Beads were washed three times in lysis buffer, resuspended in SDS sample buffer and electrophoresed on a 10% poly-acrylamide gel. Proteins pulled down using an anti-Tle2 (Santa Cruz) or anti-Hes1 (Santa Cruz) antibody were immunoblotted onto Immobilon-P membranes (Millipore) and detected with mouse anti-Nkx2-2 (Developmental Studies Hybridoma Bank), mouse anti-Nkx6-1 (Developmental Studies Hybridoma Bank), rabbit anti-Tle2 (Santa Cruz), or rabbit anti-His (Abcam). Negative controls to assess the specifity of the pulldowns included: rabbit IgG pulldowns and lysate only controls. Rat Insulin Reporter Assays Assays were performed by transfecting 2 × 105 Min6 cells with 600 ng of the appropriate vectors using Lipofectamine (Invitrogen) (pCMV-HA was used to adjust total DNA amounts) using the following amounts as appropriate: 300 ng of rat insulin promoter EGFP reporter plasmid, 50 ng of pCMS-Arx, 50 ng of pCMS-Arx Δeh1, 200 ng of pCMS-Flag-Tle2. 48 hrs after transfection the cells were harvested and single cell-suspensions prepared. Cells were then stained with 7-AAD (5 μg/ml) and analyzed by flow cytometry using a FACSCalibur flow cytometer and CELLQuest software (BD Pharmigen). Cells were gated based on the forward- versus side-scatter profile and on the 7-AAD versus forward scatter profiles to gate for viable cells, and a pCMS-HA only transfected sample was used to determine appropriate gating. The mean green fluorescence intensity was then determined for the samples using the CELLQuest software (BD Pharmingen). Authors' contributions BH performed all IHC, SAGE data analysis, and GenePaint analysis; assisted with the qRT-PCR studies and RIP assays, and wrote the manuscript. BZ performed co-immunoprecipitation experiments and assisted with the qRT-PCR studies. MB performed the Rat insulin promoter assays. CH is the senior author. All authors have read and approved the manuscript. Acknowledgements The authors would like to acknowledge the staff of the Animal Resource Center at the BBCRC. In addition we would like to thank Stefano Stifani (McGill University) for providing the anti-Tle1 and anti-Tle4 antibodies, as well as Chris Wright (Vanderbilt) for providing the anti-Pdx1 antibody. We also would like to thank James Piret (UBC) for providing us with the rat insulin promoter construct and Joy Witzsche for performing the cryosectioning. Cheryl D. Helgason is a scholar of the Michael Smith Foundation for Health Research. Funding was provided by the Genome Canada contracts "Mouse Atlas of Development" and "MORGEN", the National Institute of Health (USA), and StemCell Technologies Inc., with infrastructure support provided by the BC Cancer Foundation. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||||||||||||||||||
J Biol Chem. 2005 Apr 22; 280(16):16284-94.
[J Biol Chem. 2005]Curr Biol. 2001 Sep 18; 11(18):1413-20.
[Curr Biol. 2001]Development. 2007 Feb; 134(3):515-23.
[Development. 2007]Development. 2005 Jul; 132(13):2969-80.
[Development. 2005]Mol Endocrinol. 2004 Jun; 18(6):1363-75.
[Mol Endocrinol. 2004]Gene. 2000 May 16; 249(1-2):1-16.
[Gene. 2000]Genes Dev. 1997 Nov 15; 11(22):3072-82.
[Genes Dev. 1997]J Biol Chem. 1997 Oct 17; 272(42):26604-10.
[J Biol Chem. 1997]Mech Dev. 1995 Nov; 53(3):369-81.
[Mech Dev. 1995]Dev Growth Differ. 1998 Apr; 40(2):133-46.
[Dev Growth Differ. 1998]Cell Mol Biol (Noisy-le-grand). 1999 Jul; 45(5):687-708.
[Cell Mol Biol (Noisy-le-grand). 1999]Mol Endocrinol. 2003 Nov; 17(11):2152-61.
[Mol Endocrinol. 2003]Dev Biol. 2001 Apr 15; 232(2):315-26.
[Dev Biol. 2001]Nucleic Acids Res. 2001 Apr 1; 29(7):1410-9.
[Nucleic Acids Res. 2001]J Biol Chem. 2000 Jun 16; 275(24):18418-23.
[J Biol Chem. 2000]Mol Cell Biol. 2002 Jan; 22(2):389-99.
[Mol Cell Biol. 2002]Proc Natl Acad Sci U S A. 2005 Dec 20; 102(51):18485-90.
[Proc Natl Acad Sci U S A. 2005]Genome Biol. 2008; 9(6):R99.
[Genome Biol. 2008]Mech Dev. 2000 Jun; 94(1-2):199-203.
[Mech Dev. 2000]Nat Genet. 1999 Sep; 23(1):67-70.
[Nat Genet. 1999]Development. 2000 Dec; 127(24):5533-40.
[Development. 2000]Development. 2007 Jul; 134(13):2491-500.
[Development. 2007]Diabetologia. 2001 Oct; 44(10):1203-14.
[Diabetologia. 2001]Development. 2002 May; 129(10):2447-57.
[Development. 2002]Development. 2007 Feb; 134(3):515-23.
[Development. 2007]Cell. 2001 Mar 23; 104(6):861-73.
[Cell. 2001]Mol Endocrinol. 2004 Jun; 18(6):1363-75.
[Mol Endocrinol. 2004]J Biol Chem. 1996 Aug 2; 271(31):18749-58.
[J Biol Chem. 1996]Nat Genet. 2000 Jan; 24(1):36-44.
[Nat Genet. 2000]Nucleic Acids Res. 2001 Apr 1; 29(7):1410-9.
[Nucleic Acids Res. 2001]Mech Dev. 2000 May; 93(1-2):105-15.
[Mech Dev. 2000]Dev Dyn. 2004 Jan; 229(1):176-200.
[Dev Dyn. 2004]Development. 2002 May; 129(10):2447-57.
[Development. 2002]Eur J Biochem. 1998 Dec 1; 258(2):339-49.
[Eur J Biochem. 1998]J Biol Chem. 2002 Dec 27; 277(52):51049-57.
[J Biol Chem. 2002]Gene. 2000 May 16; 249(1-2):1-16.
[Gene. 2000]J Biol Chem. 1997 Oct 17; 272(42):26604-10.
[J Biol Chem. 1997]Mol Cell Biol. 2005 Dec; 25(24):10916-29.
[Mol Cell Biol. 2005]Development. 2005 Jul; 132(13):2969-80.
[Development. 2005]Genes Dev. 2003 Oct 15; 17(20):2591-603.
[Genes Dev. 2003]J Clin Invest. 2007 Apr; 117(4):961-70.
[J Clin Invest. 2007]Mech Dev. 2000 May; 93(1-2):105-15.
[Mech Dev. 2000]Development. 2007 Feb; 134(3):515-23.
[Development. 2007]Development. 2007 Feb; 134(3):515-23.
[Development. 2007]Dev Dyn. 2004 Jan; 229(1):176-200.
[Dev Dyn. 2004]Nat Neurosci. 2001 Nov; 4 Suppl():1183-91.
[Nat Neurosci. 2001]Cell. 2001 Mar 23; 104(6):861-73.
[Cell. 2001]Development. 2007 Feb; 134(3):515-23.
[Development. 2007]Neuron. 2001 Sep 13; 31(5):743-55.
[Neuron. 2001]Development. 2003 Sep; 130(17):4149-59.
[Development. 2003]Endocrinology. 2005 Apr; 146(4):1808-17.
[Endocrinology. 2005]Genome Biol. 2007; 8(1):R6.
[Genome Biol. 2007]Proc Natl Acad Sci U S A. 2005 Dec 20; 102(51):18485-90.
[Proc Natl Acad Sci U S A. 2005]Genome Res. 1998 Mar; 8(3):186-94.
[Genome Res. 1998]Nucleic Acids Res. 2001 May 1; 29(9):e45.
[Nucleic Acids Res. 2001]Dev Cell. 2007 Jul; 13(1):103-14.
[Dev Cell. 2007]